Skip to content

Author

Hervé Tiriac

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B006: Actin Cytoskeleton Dynamics in Tumor Cells Orchestrate Stromal Desmoplasia and Immune Evasion in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is defined by a dense, immunosuppressive tumor microenvironment (TME) enriched with extracellular matrix components, cancer-associated fibroblasts (CAFs), and diverse immune populations. ChIP-seq analysis of resected human PDAC identified MICAL2 as a super-enhancer–associat...

Bharti Garg, E. Mose, Briana Nyugen et al. · 0 citations
Sep 2026

Abstract B137: Targeting MICAL2 sensitizes pancreatic cancer cells to gemcitabine and enhances therapeutic response

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, largely due to rapid development of resistance to standard chemotherapies such as gemcitabine. MICAL2 is a redox-dependent regulator of actin dynamics that is overexpressed in PDAC, but its role in therapeutic resistance remains poorly un...

Ponmathi Panneerpandian, Kevin Christian Montecillo Gulay, M. Macdonald et al. · 0 citations
Sep 2026

Abstract B054: Combined RAS Inhibition and Immune Checkpoint Blockade Overcome NF-κB-Mediated Immune Evasion in Chemoresistant Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Surgery is the only potentially curative treatment, yet approximately 85% of patients present with unresectable disease. For these patients, chemotherapy remains the standard treatment, though nearly all develop resistance and diseas...

K. Gulay, A. Martsinkovskiy, A. Lowy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.